Literature DB >> 28953788

Benzodiazepines in combination with antipsychotic drugs for schizophrenia: GABA-ergic targeted therapy.

Adam Włodarczyk1, Joanna Szarmach, Wiesław Jerzy Cubała, Mariusz Stanisław Wiglusz.   

Abstract

Antipsychotics are a key intervention strategy in pharmacotherapy of schizophrenia. However, benzodiazepines are often prescribed to control sleep disturbances, anxiety or behavioural disinhibition. There is clinical evidence for the beneficial effect of the combined treatment of antipsychotics and benzodiazepines resulting in more favorable treatment outcome in schizophrenia with regard to positive and negative symptoms. This clinical phenomenon seems to be associated with the GABA-ergic activit ythat is believed to be disrupted in the schizophrenia and direct benzodiazepines effect on GABA-A receptors. In the brain there are both excitatory and inhibitory neurotransmitters which cooperate between themselves maintaining the proper functioning of the brain. GABA neurons carry inhibitory signals that help keep brain activity at optimal levels of operation, Glutamate, on the other hand, carry excitatory signals. As the interplay between these two exists they keep the dopamine levels in the average levels. The disruption of GABA-ergic transmission in schizophrenia may induce alternations in dopaminergic neurotransmission providing no inhibitory effect to the central glutamate activity, resulting in the rise of the dopamine levels being associated with psychosis precipitation. Benzodiazepines are believed to reduce presynaptic dopamine release at the mesolimbic level and delay postsynaptic adaptation of dopaminergic neurons to antipsychotics potentiating the action of antipsychotics in resistant schizophrenia. Benzodiazepines also act on mesocortical regions where antipsychotics are less effective and where there is a particular sensitivity to stress. This association is particularly useful in resistant patients or in patients with severe anxiety with or without intolerance to antipsychotics. Improvement concerns anxious symptoms but also positive symptoms (hallucinations, delirium and dissociative syndrome) and negative (social withdrawal, affect flattening). As the available studies are limited there is some clinical evidence that the use of antipsychotic drugs with addition of benzodiazepines can provide better general outcome in ill patients than antipsychotics administration alone.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28953788

Source DB:  PubMed          Journal:  Psychiatr Danub        ISSN: 0353-5053            Impact factor:   1.063


  5 in total

1.  Molecular mechanisms involved in the prevention and reversal of ketamine-induced schizophrenia-like behavior by rutin: the role of glutamic acid decarboxylase isoform-67, cholinergic, Nox-2-oxidative stress pathways in mice.

Authors:  Tolulope Olabode Oshodi; Benneth Ben-Azu; Ismail O Ishola; Abayomi Mayowa Ajayi; Osagie Emokpae; Solomon Umukoro
Journal:  Mol Biol Rep       Date:  2021-04-03       Impact factor: 2.316

2.  Long-Term Antipsychotic Effectiveness and Comparison of the Efficacy of Monotherapy and Polypharmacy in Schizophrenia: A 3-Years Follow-Up "Real World" Study in China.

Authors:  Lei Zhang; Sidi He; Luyao He; Wenjuan Yu; Shen He; Yange Li; Yimin Yu; Qingshan Zheng; Jingjing Huang; Yifeng Shen; Huafang Li
Journal:  Front Pharmacol       Date:  2022-06-13       Impact factor: 5.988

3.  An Efficient Synthetic Approach Towards Benzo[b]pyrano[2,3-e][1,4]diazepines, and Their Cytotoxic Activity.

Authors:  Islam H El Azab; Nadia A A Elkanzi
Journal:  Molecules       Date:  2020-04-28       Impact factor: 4.411

4.  Use of Benzodiazepines and Antipsychotic Drugs Are Inversely Associated With Acute Readmission Risk in Schizophrenia.

Authors:  Maria F Strømme; Liv S Mellesdal; Christoffer A Bartz-Johannesen; Rune A Kroken; Marianne L Krogenes; Lars Mehlum; Erik Johnsen
Journal:  J Clin Psychopharmacol       Date:  2022 Jan-Feb 01       Impact factor: 3.153

5.  Timing of antipsychotics and benzodiazepine initiation during a first episode of psychosis impacts clinical outcomes: Electronic health record cohort study.

Authors:  Maite Arribas; Marco Solmi; Trevor Thompson; Dominic Oliver; Paolo Fusar-Poli
Journal:  Front Psychiatry       Date:  2022-09-23       Impact factor: 5.435

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.